Yamani Hend Z, Hassan Yasmine H, Magdy Nancy, Abdel Ghany Maha F, Gomaa Mohammed M
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Solid State Physics Department, National Research Centre, Giza, 12622, Egypt.
Mikrochim Acta. 2025 May 26;192(6):374. doi: 10.1007/s00604-025-07235-5.
An electrochemical sensing platform based on a nickel metal-organic framework/carbon nanotubes (Ni-MOF/CNTs) nanocomposite has been developed for the determination of sotagliflozin, the first dual sodium-glucose co-transporter inhibitor recently approved by the FDA. The nanocomposite was synthesized using a simple one-pot solvothermal method and characterized by Raman spectroscopy, Fourier-transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), scanning electron microscope (SEM), and electrochemical impedance spectroscopy (EIS). The Ni-MOF/CNTs nanocomposite demonstrates superior electrochemical properties compared with its monocomponent counterparts, due to the synergistic combination of the advantages of both materials. The electrochemical behavior and the oxidation mechanism of sotagliflozin at the electrode surface were investigated using cyclic voltammetry (CV). Under optimal conditions, the sensor exhibits wide linearity across two concentration ranges: 8.0 × 10 to 6.0 × 10 M and 6.0 × 10 to 8.0 × 10 M, using differential pulse voltammetry (DPV) with a detection limit of 2.65 × 10 M. Good recoveries (96.60-102.83%) were achieved in human plasma, urine, and tablets. The whiteness assessment confirms the method's sustainability, while the blueness assessment demonstrates its applicability. The sensor's outstanding performance addresses the unmet need for a simple and accurate tool for sotagliflozin determination in biological and pharmaceutical samples, as no existing analytical methods are available for its determination in different matrices. This makes it a valuable tool for sotagliflozin therapeutic drug monitoring, point-of-care diagnostics, and quality control.
一种基于镍金属有机框架/碳纳米管（Ni-MOF/CNTs）纳米复合材料的电化学传感平台已被开发用于测定索格列净，它是美国食品药品监督管理局（FDA）最近批准的首个双靶点钠-葡萄糖协同转运蛋白抑制剂。该纳米复合材料采用简单的一锅溶剂热法合成，并通过拉曼光谱、傅里叶变换红外光谱（FTIR）、X射线光电子能谱（XPS）、扫描电子显微镜（SEM）和电化学阻抗谱（EIS）进行表征。由于两种材料优势的协同结合，Ni-MOF/CNTs纳米复合材料与其单一组分相比表现出优异的电化学性能。使用循环伏安法（CV）研究了索格列净在电极表面的电化学行为和氧化机理。在最佳条件下，该传感器在两个浓度范围内呈现宽线性：8.0×10至6.0×10 M和6.0×10至8.0×10 M，采用差分脉冲伏安法（DPV），检测限为2.65×10 M。在人血浆、尿液和片剂中实现了良好的回收率（96.60 - 102.83%）。白度评估证实了该方法的可持续性，而蓝度评估证明了其适用性。该传感器的出色性能满足了在生物和药物样品中测定索格列净时对简单准确工具的未满足需求，因为目前尚无用于在不同基质中测定它的现有分析方法。这使其成为索格列净治疗药物监测、即时诊断和质量控制的有价值工具。
